Online inquiry

IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3989MR)

This product GTTS-WQ3989MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets LTB&TNFSF14 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002341.2; NM_003807.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4050; 8740
UniProt ID Q06643; O43557
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3989MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8133MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HH1
GTTS-WQ9427MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IPH-2201
GTTS-WQ9129MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMGN242
GTTS-WQ11016MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MCLA-117
GTTS-WQ13290MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06523435
GTTS-WQ10895MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MABp1
GTTS-WQ1190MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABP 980
GTTS-WQ366MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 20A11-9mer-ALB11
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW